LIFE LAB PHARMA AS
Score · fiscal year 2025
48of 100
How to read this: the company is ahead of 45 % of small companies in the same sector in 2025. What does this mean?
Rank: 21,322 of 38,671 · Handel
Profile
Cheetah · Sprinter
High profitability, lower solidity
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 72 and solidity 0 out of 100 among small companies in the same sector in 2025. Methodology
Against the sector
LIFE LAB PHARMA AS is 2 points below the median for small companies in the same sector in 2025.
Median score 50 among 36,111 companies.
Against small companies in the same sector in 2025: operating margin 5.6% (median 2.5%) and equity ratio −11.4% (median 38.3%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 8 MNOK | 3 MNOK |
| Operating margin | 5.6% | 2.5% |
| Profit margin | 4.3% | 2.2% |
| Return on assets | 19.2% | 4.0% |
| Equity ratio | −11.4% | 38.3% |
| Debt-to-equity | – | 0.99 |
| Current ratio | 0.91 | 1.70 |
| Revenue growth | 520.2% | 3.5% |
The median and “ahead of” refer to small companies in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 48, LIFE LAB PHARMA AS does better than 45% of small companies in the same sector (36,580 companies) in 2025.
Score 2024–2025
- LIFE LAB PHARMA AS
- Median: small companies in the same sector
LIFE LAB PHARMA AS has a score of 48 for 2025, rank 21,322 of 38,671 in the sector.
Strongest: Growth: percentile 97 against peers, revenue growth 520.2% against a median of 3.5%. Profitability: percentile 72 against peers, operating margin 5.6% against a median of 2.5%.
Weakest: Solidity: percentile 0 against peers, equity ratio −11.4% against a median of 38.3%. Liquidity: percentile 21 against peers, current ratio 0.91 against a median of 1.70.
Worth a closer look
- Equity is negative. How will it be rebuilt, and what do lenders and the auditor say about going concern? Based on: equity ratio −11.4% (median 38.3%).
- Consider strengthening liquidity: current liabilities are 1.1 times current assets. Based on: current ratio 0.91 (median 1.70).
- Strong growth with weak liquidity. Is the growth financed, or does it tie up capital the company does not have? Based on: revenue growth 520.2% (median 3.5%); current ratio 0.91 (median 1.70).
- What lies behind weak solidity, and will it last?
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
What the numbers say
LIFE LAB PHARMA AS had an operating margin of 5.6% and an equity ratio of −11.4% in 2025, and ranks 21,322 of 38,671 in Handel.
From 2024 to 2025: revenue grew by 520% and the operating margin rose from −55.5% to 5.6%.
This text is generated automatically from the 2025 accounts.
Three simple methods
The methods give between 3 MNOK and 4 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 3 MNOK |
| EV/EBIT | 8.0 | 4 MNOK |
| P/B | 1.0 | not meaningful |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
- critical
Equity is negative. How will it be rebuilt, and what do lenders and the auditor say about going concern?
Based on: Equity ratio −11.4% (median 38.3%).
- watch
Consider strengthening liquidity: current liabilities are 1.1 times current assets.
Based on: Current ratio 0.91 (median 1.70).
- watch
Strong growth with weak liquidity. Is the growth financed, or does it tie up capital the company does not have?
Based on: Revenue growth 520.2% (median 3.5%); Current ratio 0.91 (median 1.70).
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 4.3% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
Data quality
- critical Negative equity
Scenario analysis: the sector's weakest year
We have no accounts for 2017, the sector's weakest year, for this company.
The sector's weakest year was 2017, with a median operating margin of −65.6%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 72 | weight 30% |
|---|---|---|
| Solidity | 0 | weight 25% |
| Liquidity | 21 | weight 15% |
| Growth | 97 | weight 15% |
| Consistency | 55 | weight 15% |
Durability: 28 (average over 2 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is LIFE LAB PHARMA AS?
The operating margin was 5.6% in 2025, against a median of 2.5% among small companies in the same sector. Return on assets was 19.2%.
How solid is LIFE LAB PHARMA AS?
The equity ratio was −11.4% in 2025 (median 38.3%). Equity is negative, so liabilities exceed assets.
What is the liquidity of LIFE LAB PHARMA AS like?
The current ratio was 0.91 in 2025 (median 1.70). Current assets did not cover current liabilities.
How does LIFE LAB PHARMA AS compare in Handel?
LIFE LAB PHARMA AS ranks 21,322 of 38,671 in Handel for 2025. Among companies of the same size (small companies) it ranks 19,937 of 36,580. Revenue changed by 520.2% from the year before.
From the Central Coordinating Register
- Org. no.
- 933332039
- Legal form
- AS
- Sector
- Handel (47.270)
- Size tier
- small
- Employees
- 0–4 (not registered)
- Founded
- 4 April 2024 2 years in operation
- Share capital
- 0.10 MNOK
- Business address
- Bekkeveien 163, 3173 VEAR (TØNSBERG)
- Municipality
- Tønsberg rank 2 of 10 in KOSTRA group 11
- Latest accounts filed
- 2025
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
- Chief executive
- Dag Tore Skjøthaug
- Chair of the board
- Daniel Helmut Podpeskar-Johansen
- Board member
- Terje Andre Skulbru
- Auditor
- REVICOM AS
- Accountant
- SYNEGA REGNSKAP AS
Source: Central Coordinating Register, fetched 25 October 2026. Only names are shown.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 27 October 2026.
Year by year · 2024–2025
| Key figure | 2024 | 2025 | Trend |
|---|---|---|---|
| Index | 8 | 48 | |
| Rank | 35,943 | 21,322 | |
| Operating margin | −55.5% | 5.6% | |
| Return on assets | −61.4% | 19.2% | |
| Equity ratio | −53.2% | −11.4% | |
| Current ratio | 0.65 | 0.91 | |
| Revenue growth | – | 520.2% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2024 | 2025 |
|---|---|---|
| Operating revenue | 1.3 MNOK | 7.9 MNOK |
| Operating profit | −0.7 MNOK | 0.4 MNOK |
| Profit before tax | −0.7 MNOK | 0.3 MNOK |
| Net profit | −0.7 MNOK | 0.3 MNOK |
| Financial expenses | 0.0 MNOK | 0.1 MNOK |
| Total assets | 1.2 MNOK | 2.4 MNOK |
| Current assets | 1.2 MNOK | 2.4 MNOK |
| Equity | −0.6 MNOK | −0.3 MNOK |
| Retained earnings | −0.7 MNOK | −0.4 MNOK |
| Total liabilities | 1.8 MNOK | 2.6 MNOK |
| Current liabilities | 1.8 MNOK | 2.6 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 27 October 2026, accounts id 6396665.
Further
Similar companies
- RK STÅL AS index 48, rank 21,320 · compare
- TONJE - WEST DESIGN AS index 48, rank 21,321 · compare
- LOFOTEN SYNSSENTER AS index 48, rank 21,323 · compare
- MANIVA HANDEL AS index 48, rank 21,324 · compare
- PÅL IVERSEN HOLDING AS index 48, rank 21,326 · compare